What commercial telomere-length tests can and cannot tell you about ageing

A commercial telomere test reads the length of the repetitive DNA caps on your chromosomes and reports it back as a kind of cellular age, on the premise that longer is younger and better. The evidence does not support that reading for an individual: the measurement is noisy and method-dependent [s2][s3], and, more awkwardly for the sales pitch, genetically longer telomeres are associated with higher — not lower — risk of several cancers [s1].

Telomeres shorten a little each time a cell divides, and average length across a tissue does fall with age, which is why it is studied as a biomarker of ageing at all [s2]. But a population average is not a personal readout. A review of measurement techniques notes that average, short and long telomere length carry distinct meanings — average length tracks ageing broadly, short telomeres flag the risk of age-related disease, and long telomeres are associated with certain cancers and with all-cancer mortality — so the distribution matters far more than the single average number a consumer test returns [s2].

Longer is not simply better

The clearest challenge to the "longer equals younger" story comes from genetics. A 2017 Mendelian randomization study used inherited gene variants that raise telomere length as instruments — a design that sidesteps the confounding and reverse-causation that plague ordinary observational studies — and pooled summary data covering 420,081 cancer cases and 1,093,105 controls across 35 cancers, plus 48 non-neoplastic diseases [s1]. Genetically increased telomere length was generally associated with a higher risk of site-specific cancers [s1]. Per one standard deviation of longer telomeres, the odds ratio was 5.27 for glioma (95% CI, 3.15–8.81), 3.19 for lung adenocarcinoma (2.40–4.22) and 1.87 for melanoma (1.55–2.26) [s1].

The picture flips for some non-cancer conditions: longer telomeres were associated with lower odds of coronary heart disease (OR 0.78; 95% CI, 0.67–0.90) [s1]. That is the real biology — a trade-off, not a dial where more is uniformly good. A test that sells a longer number as an unqualified win is describing a fantasy version of the science.

The number itself is unstable

Even setting aside what length means, there is the question of whether the test measures it reliably. The cheap, high-throughput method behind most large studies and consumer products is quantitative PCR, and it is sensitive to how the DNA was handled. A 2026 methods study showed that differences in DNA integrity introduced during extraction significantly distort qPCR telomere estimates: as template DNA degrades, the shift in long and short fragments disrupts the cycle-threshold values the assay depends on [s3]. The authors found that an extra gel-purification step gave the most stable results with the lowest coefficient of variation [s3] — useful in a controlled laboratory, and a reminder of how much a single number can move with sample handling alone.

That instability is why length is reported as relative in most work, and why comparing a result from one company against a friend's from another, or against yourself a year later, is not meaningful. Single-molecule techniques that measure telomeres one at a time can produce the full distribution rather than an average, and are advancing quickly [s2] — but they are research tools, not the saliva-tube products sold direct to consumers.

What a consumer result can support

Very little that is actionable. There is no telomere-lengthening intervention with proven benefit for a healthy person to point the number at, and — given the cancer associations — "make my telomeres longer" is not even an unambiguously desirable goal [s1]. The result cannot diagnose a disease, cannot set a treatment, and cannot be compared across labs or reliably tracked over time [s2][s3].

The honest summary is that telomere length is a real feature of ageing biology being sold as a personal odometer it is not. It shares the core failure of the broader biological-age testing market: a marker built to predict risk across populations, repackaged as a verdict about one person. It sits alongside the reliability problems of epigenetic clocks and belongs to the same list of ageing mechanisms — including telomere attrition itself — that describe how bodies age without yet telling any individual what to do about it.

This article describes research findings and is not medical advice.